将多基因评分整合到指南推荐的心血管疾病预测中
本研究在UK Biobank(n=432 981)中计算冠状动脉疾病多基因风险评分(PRS),并在Framingham/ARIC(n=10 757)中验证。结果显示SCORE2与PRS对CVD风险无显著交互作用,符合乘法模型「SCORE2×PRS-factor」;该模型可将9.55%的中危个体重新分类为高危,且重新分类者CVD发生率(8.08%)约为保持中危者(4.08%)的两倍。
要点
- SCORE2与PRS对CVD风险无显著交互作用,两者提供独立信息。
- 乘法模型「SCORE2×PRS-factor」可改善指南推荐工具的风险预测精度。
- PRS-factor可将部分中危个体重新分类为高危,重新分类者事件率更高。
核心结论
- 由临床风险评分决定的绝对CVD风险与由PRS决定的相对遗传风险提供独立信息。
- 两者可构成简单乘法模型,提高指南推荐工具预测新发CVD的精度。
研究设计与样本
- 在UK Biobank参与者(n=432 981)中计算冠状动脉疾病PRS。
- 在Framingham/ARIC合并人群(n=10 757)中进行复制验证。
- 比较不同PRS十分位内CVD的OR,并测试乘法模型「SCORE2×PRS-factor」的风险重分类效果。
主要发现
- 在临床风险差异很大的亚组中,各PRS十分位内的CVD OR保持稳定。
- SCORE2与PRS对CVD风险无显著交互作用,符合乘法关系:SCORE2×PRS-factor=总风险。
- UK Biobank中乘法模型将9.55%的中危个体(n=145 337)移至高危组,使该类别个体增加56.6%。
- 经PRS-factor从中危重分类为高危的个体CVD发生率为8.08%,约为保持中危者(4.08%)的两倍。
- Framingham/ARIC中PRS-factor将8.29%的个体从中危移至高危。
临床怎么用
- 可考虑将CAD的PRS以乘法因子形式与SCORE2联合使用,以细化CVD风险分层。
- 联合模型有助于识别按SCORE2 alone评为中危但遗传风险较高、可能受益于强化预防的个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: It is not clear how a polygenic risk score (PRS) can be best combined with guideline-recommended tools for cardiovascular disease (CVD) risk prediction, e.g. SCORE2. METHODS: A PRS for coronary artery disease (CAD) was calculated in participants of UK Biobank (n = 432 981). Within each tenth of the PRS distribution, the odds ratios (ORs)-referred to as PRS-factor-for CVD (i.e. CAD or stroke) were compared between the entire population and subgroups representing the spectrum of clinical risk. Replication was performed in the combined Framingham/Atherosclerosis Risk in Communities (ARIC) populations (n = 10 757). The clinical suitability of a multiplicative model 'SCORE2 × PRS-factor' was tested by risk reclassification. RESULTS: In subgroups with highly different clinical risks, CVD ORs were stable within each PRS tenth. SCORE2 and PRS showed no significant interactive effects on CVD risk, which qualified them as multiplicative factors: SCORE2 × PRS-factor = total risk. In UK Biobank, the multiplicative model moved 9.55% of the intermediate (n = 145 337) to high-risk group increasing the individuals in this category by 56.6%. Incident CVD occurred in 8.08% of individuals reclassified by the PRS-factor from intermediate to high risk, which was about two-fold of those remained at intermediate risk (4.08%). Likewise, the PRS-factor shifted 8.29% of individuals from moderate to high risk in Framingham/ARIC. CONCLUSIONS: This study demonstrates that absolute CVD risk, determined by a clinical risk score, and relative genetic risk, determined by a PRS, provide independent information. The two components may form a simple multiplicative model improving precision of guideline-recommended tools in predicting incident CVD.
引用
- Li L, Pang S, Starnecker F, et al. Integration of a polygenic score into guideline-recommended prediction of cardiovascular disease. Eur Heart J. 2024. PMID: 38551411. doi:10.1093/eurheartj/ehae048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。